Automated Insulin Delivery

This systematic review and meta-analysis used a literature search to gather data from long-term randomized controlled trials on the effectiveness of closed-loop insulin systems (CLS) among nonpregnant patients with type 1 diabetes (T1D).

This new study investigated and compared the incidence of disordered eating behavior (DEB) among 2 cohorts of patients with type 1 diabetes (T1D) treated with continuous-subcutaneous insulin infusion (CSII) or a basal-bolus regimen.

Investigators fashioned a zone-model predictive controller to evaluate adjustment of closed-loop glycemic control during pregnancy, as both glycemic control and insulin adjustment continually change throughout gestation.

This new literature review explored the potential to enhance management for type 1 diabetes (T1D) through the adoption of physiological parameters measured by wearable and sensor-enabled health-related technology.

Improvements in time spent in target range and glycated hemoglobin A1c were investigated among 34 children with type 1 diabetes (T1D) with a history of daily insulin use and no prior use of diabetes technology.

This new study evaluated the impact of a virtual endocrinology care program on time in range and outcomes among individuals with poorly controlled diabetes who are novice users of continuous glucose monitoring.

Why persons with type 1 diabetes and continuous insulin infusion fail to achieve optimal glycemic control was the subject of a recent focus group analysis conducted among 37 adult men and women.

Because type 1 diabetes can be very difficult to effectively manage in children and adolescents, these study investigators compared outcomes between a hybrid closed-loop algorithm add-on and usual care.

This subanalysis of participant data from the OPEN project investigated relationships between glycemic levels and insulin requirements among women with type 1 diabetes and phases of their menstrual cycle.

Data from continuous glucose monitors were used to measure glycemic variability among patients with type 2 diabetes (T2D) and community-acquired pneumonia (CAP) hospitalized in Denmark between February and June 2021.

This new study from Germany evaluated the use of and satisfaction with continuous glucose monitors (CGMs) since health insurance companies in the country began reimbursement of the technology in 2016 for persons with insulin-dependent diabetes.

This new investigation compared outcomes among pediatric patients with type 1 diabetes (T1D) before and after COVID-19 restrictions were imposed in Dallas County on March 15, 2020.

This new investigation evaluated outcomes among 6 youths with type 1 diabetes, who had public insurance coverage and received continuous glucose monitoring assistance through the CGM Time in Range Program.

This new investigation from the United Kingdom evaluated health care professionals’ (HCP) perceptions and implementation of practices that focus on open-source automated insulin delivery (OS-AID).

This new study of pediatric patients with type 1 diabetes from France and Belgium investigated the effectiveness of insulin delivery via closed-loop and open-loop systems.

The insulin delivery system was linked with a reduction in hypoglycemia among adults and a decrease in hyperglycemia in both adults and children.

Findings about the willingness of primary care providers to prescribe artificial pancreas systems have positive implications for increasing access to and reducing disparities around this technology by alleviating the need to see a specialist.

The findings, said the researchers, are an important step toward achieving glucose control with a fully automated closed-loop system for patients with type 1 diabetes.

Authors from the University of Colorado say factors from skin irritations, to cost, to lack of insurance coverage, to physician barriers have limited uptake of automated insulin delivery systems.

Clinicians should be willing to work with patients eager to try “do-it-yourself” insulin systems, but should also warn them of the risks, the guidelines state.

An open-label randomized trial found patients using the closed-loop system had more time in their target glucose ranges.

Lower indirect costs and a lower incidence of serious complications offset the higher cost of the advanced hybrid closed-loop insulin system.

Analysis of the MarketScan database showed a strong association between flash continuous glucose monitoring (CGM) use and significant reductions in diabetes-related events and hospitalizations in a cohort of 10,282 adults with type 2 diabetes.

Although the authors say their findings shed light on possible disruptions to insulin supply during COVID-19, they note they could not adjust for those with diabetes who died.